Inclusion Criteria:

          -  Histologically confirmed locally advanced or metastatic clear cell or non-clear cell
             (papillary and unclassified only) RCC. RCC with sarcomatoid features is allowed.

          -  Radiographic disease progression during or following treatment with ICI for locally
             advanced or metastatic RCC either in first- or second-line treatment. ICI is defined
             by anti-PD-L1 or anti-PD1 antibody including atezolizumab, avelumab, pembrolizumab, or
             nivolumab. Only patients for whom the immediate preceding line of therapy was an ICI
             are allowed.

          -  Measurable disease per RECIST v1.1

          -  Evaluable IMDC risk score

          -  Archival tumor specimen, and pretreatment tumor tissue from fresh biopsy at screening,
             if clinically feasible

          -  KPS score of >=70

          -  Adequate hematologic and end-organ function

          -  Negative HIV test at screening

          -  Negative hepatitis B testing at screening

          -  Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody
             test followed by a negative HCV RNA test at screening

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraception and agreement to refrain from donating
             eggs

          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
             a condom, and agreement to refrain from donating sperm

        Exclusion Criteria:

          -  Treatment with anti-cancer therapy within 28 days prior to initiation of study
             treatment

          -  Patients received cabozantinib at any time prior to screening

          -  Patients who received more than 1 regimen of ICIs

          -  Patients who received more than 2 prior lines of therapy in the advanced or metastatic
             setting

          -  Patients who received ICI in the adjuvant setting (adjuvant VEGFR-TKI except
             cabozantinib is allowed)

          -  Patients who have received a mammalian target of rapamycin (mTOR) inhibitor in the
             advanced or metastatic setting

          -  Symptomatic, untreated, or actively progressing CNS metastases

          -  History of leptomeningeal disease

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures

          -  Uncontrolled or symptomatic hypercalcemia or symptomatic hypercalcemia requiring
             continued use of bisphosphonate therapy or denosumab

          -  History of malignancy other than renal carcinoma within 5 years prior to screening,
             with the exception of malignancies with a negligible risk of metastasis or death

          -  Radiotherapy for RCC within 14 days prior to Day 1 of Cycle 1

          -  Active tuberculosis

          -  Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation
             of study treatment, or anticipation of need for a major surgical procedure during the
             study

          -  Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment
             or within 5 months after final dose of atezolizumab and 4 months after final dose of
             cabozantinib

          -  Severe infection within 4 weeks prior to initiation of study treatment, including, but
             not limited to, hospitalization for complications of infection, bacteremia, or severe
             pneumonia

          -  Uncontrolled hypertension defined as sustained blood pressure >150 mm Hg systolic or >
             90 mm Hg diastolic despite optimal antihypertensive treatment

          -  Significant cardiovascular disease (such as New York Heart Association Class II or
             greater cardiac disease, MI, or cerebrovascular accident) within 3 months prior to
             initiation of study treatment, unstable arrhythmia, or unstable angina

          -  Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or
             recent peripheral arterial thrombosis) within 6 months prior to Day 1 of Cycle 1

          -  History of congenital QT syndrome

          -  History or presence of an abnormal ECG that is clinically significant in the
             investigator's opinion

          -  Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin
             inhibitor dabigatran, direct factor Xa inhibitor betrixaban, or platelet inhibitors
             (e.g. clopidogrel)